Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.

PURPOSE This was a pilot study conducted to examine the expression of osteopontin in uveal melanoma and to determine whether serum osteopontin can be used in detecting metastatic uveal melanoma. METHODS Osteopontin mRNA was measured in three uveal melanoma cell lines of various invasive potential by real-time PCR. Tissue sections of primary and metastatic uveal melanomas were stained for osteopontin. Serum osteopontin levels were measured by ELISA assays in 15 patients with metastatic uveal melanoma and in 37 patients who were disease-free for at least 10 years after treatment of the primary tumor. Paired serum samples drawn from eight patients before and after development of metastasis were analyzed. RESULTS By real-time PCR, highly invasive primary and metastatic uveal melanoma cells expressed 6- and 250-fold excess osteopontin mRNA, respectively, compared with poorly invasive primary uveal melanoma cells. Tissue sections of primary uveal melanomas lacking looping vasculogenic mimicry patterns either did not stain for osteopontin or exhibited weak, diffuse staining. In primary melanomas containing looping vasculogenic mimicry patterns, strong osteopontin staining was detected in the tumor periphery where patterns were located. Diffuse strong expression of osteopontin was detected in eight samples of uveal melanomas metastatic to the liver. Serum osteopontin levels were significantly higher in patients with metastatic uveal melanoma than in patients who had been disease free for at least 10 years after treatment (P = 0.0001) or in age-matched control subjects. Serum osteopontin levels were significantly higher (P = 0.008) after metastasis than before the detection of metastasis in eight patients. When a cutoff of 10 ng/mL was used, the sensitivity and specificity of serum osteopontin in detecting metastatic melanoma was 87.5%, and the area under the receiver operator characteristic curve was 96%. CONCLUSIONS Osteopontin is expressed diffusely in tissue sections of hepatic metastases from uveal melanoma, and increased serum osteopontin levels correlate with melanoma metastasis to the liver with high specificity and sensitivity.

[1]  R. Folberg,et al.  Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. , 2005, American journal of ophthalmology.

[2]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[3]  M. Del Vecchio,et al.  Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. , 2004, Endocrine-related cancer.

[4]  Justis P. Ehlers,et al.  Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death , 2004, Cancer Research.

[5]  P. Kuo,et al.  The role of Osteopontin in tumor metastasis. , 2004, The Journal of surgical research.

[6]  A. Sundan,et al.  Role of osteopontin in adhesion, migration, cell survival and bone remodeling. , 2004, Experimental oncology.

[7]  Ming-Hui Chen,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.

[8]  J. Pe’er,et al.  Liver function tests in metastatic uveal melanoma. , 2004, American journal of ophthalmology.

[9]  H. Asaoku,et al.  Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications , 2003, British journal of haematology.

[10]  M. Hendrix,et al.  Molecular plasticity of human melanoma cells , 2003, Oncogene.

[11]  K. Jöckel,et al.  Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. , 2003, Cancer research.

[12]  R. Hruban,et al.  Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  I. Grierson,et al.  Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. , 2003, Investigative ophthalmology & visual science.

[14]  A. Bosserhoff,et al.  Melanoma inhibitory activity: a novel serum marker for uveal melanoma , 2002, Melanoma research.

[15]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[16]  S. Hirohashi,et al.  Overexpression of osteopontin in hepatocellular carcinoma , 2002, Pathology international.

[17]  N. Fedarko,et al.  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  A. Chambers,et al.  The Role of Osteopontin in Breast Cancer: Clinical and Experimental Studies , 2001, Journal of Mammary Gland Biology and Neoplasia.

[19]  A. Tarkkanen,et al.  Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. , 2001, Investigative ophthalmology & visual science.

[20]  H. Boldt,et al.  Microcirculation patterns other than loops and networks in choroidal and ciliary body melanomas. , 2001, Ophthalmology.

[21]  R Folberg,et al.  Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.

[22]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[23]  T. Kivelä,et al.  Screening for metastatic malignant melanoma of the uvea revisited , 1999, Cancer.

[24]  A. Tarkkanen,et al.  Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. , 1999, Journal of the National Cancer Institute.

[25]  S. Seregard,et al.  Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. , 1998, Ophthalmology.

[26]  W. Stolz,et al.  Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. , 1997, Cancer research.

[27]  M. Burnier,et al.  Uveal melanoma: Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size , 1997 .

[28]  F. O'Malley,et al.  Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Y. Ohnishi,et al.  Histologic findings and prognosis of uveal malignant melanoma in japanese patients. , 1996, American journal of ophthalmology.

[30]  E. Manseau,et al.  Osteopontin expression and distribution in human carcinomas. , 1994, The American journal of pathology.

[31]  R. Folberg,et al.  The prognostic value of tumor blood vessel morphology in primary uveal melanoma. , 1993, Ophthalmology.

[32]  N. Rao,et al.  Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. , 1989, Investigative ophthalmology & visual science.

[33]  M. Hendrix,et al.  A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. , 1987, Cancer letters.

[34]  L. Donoso,et al.  Metastatic uveal melanoma: diffuse hepatic metastasis in a patient with concurrent normal serum liver enzyme levels and liver scan. , 1985, Archives of ophthalmology.

[35]  D. Char.  Metastatic choroidal melanoma. , 1978, American journal of ophthalmology.

[36]  Margaret M. Fleck,et al.  Mapping the location of prognostically significant microcirculatory patterns in ciliary body and choroidal melanomas , 2008, Pathology & Oncology Research.

[37]  I. McLean.  The biology of haematogenous metastasis in human meal malignant melanoma , 2005, Virchows Archiv A.

[38]  D. Denhardt.  Osteopontin expression correlates with melanoma invasion. , 2005, The Journal of investigative dermatology.

[39]  R. Folberg,et al.  Tumorigenesis and Neoplastic Progression Chromatin Organization Measured by Alu I Restriction Enzyme Changes with Malignancy and Is Regulated by the Extracellular Matrix and the Cytoskeleton , 2005 .

[40]  S. Rittling,et al.  Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. , 2004, Cellular immunology.

[41]  P. Meltzer,et al.  Molecular determinants of human uveal melanoma invasion and metastasis , 2004, Clinical & Experimental Metastasis.

[42]  A. Foss,et al.  Predictive power of screening tests for metastasis in uveal melanoma , 1998, Eye.